TEST:

Prosigna® Breast Risk of Recurrence (ROR) Test

No significant interactions were observed by molecular subtype, nodal status, or grade, although a nonsignificant trend toward stronger iTIL effects appeared in luminal B tumors. AI-based TIL quantification thus provides independent prognostic information in high-risk luminal breast cancer.

P2, N=671, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: May 2026 --> May 2030 | Trial primary completion date: May 2026 --> May 2030

P3, N=27, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Jun 2026 --> Sep 2026

P3, N=61, Terminated, SOLTI Breast Cancer Research Group | N=456 --> 61 | Trial completion date: Mar 2027 --> Mar 2026 | Active, not recruiting --> Terminated; The study was prematurely halted because enrollment was significantly delayed compared with the original projections due to the evolving therapeutic landscape.

Translating these findings to human breast cancer (TCGA-BRCA), a prognostic model combining clinical variables (age, metastasis, PAM50 subtype) with three-gene expression (OLR1, PCSK6, and GALNT6) significantly improved patient risk stratification (P = 0.015). By integrating multi-omics analyses (scRNA-seq, TCGA) with an aggressive Tn+ TNBC model, this study defines a novel three-gene prognostic signature that links the glyco-miRNA axis to tumor aggressiveness, offering a promising tool for advanced patient stratification and the development of precision glyco-therapeutics.

P3, N=586, Active, not recruiting, NRG Oncology | Recruiting --> Active, not recruiting

We show that male BC does not align with female BC in the same way that intrinsic subtypes of female BC are not identical. As BC heterogeneity is well recognised, we propose that male BC should be considered as a potentially unique clinical subtype of BC.

Ranks and word2vec embeddings derived from relative gene expression order enable machine learning models to robustly classify breast cancer subtypes. They address technical variability by reducing dependence on cohort-wide normalization, thereby supporting reliable subtype classification in diverse clinical settings.

P2, N=40, Recruiting, Icahn School of Medicine at Mount Sinai | Trial primary completion date: Dec 2026 --> Dec 2027

P=N/A, N=750, Completed, Novartis Pharmaceuticals

P3, N=1556, Suspended, Alliance for Clinical Trials in Oncology | N=1156 --> 1556

PDZK1 functions as a regulator of HER2 stability and may serve as a potential biomarker and therapeutic target in HER2-positive breast cancer. Pharmacological upregulation of PDZK1 may represent a promising combinatorial therapeutic strategy for overcoming therapeutic resistance in breast cancer.